APPENDIX
I. BIOLOGICAL
CONTAINMENT (See Appendix E, Certified Host-Vector Systems)
Appendix I-I. Levels
of Biological Containment
Appendix I-I-A. Host-Vector
1 Systems
Appendix I-I-A-1. Escherichia coli K-12 Host-Vector 1
Systems (EK1)
Appendix I-I-A-2. Other
Host-Vector 1 Systems
Appendix I-I-B. Host-Vector
2 Systems (EK2)
Appendix I-II. Certification
of Host-Vector Systems
Appendix I-II-A. Responsibility
Appendix I-II-B. Data
to be Submitted for Certification
Appendix I-II-B-1. Host-Vector
1 Systems Other than Escherichia coli K-12
Appendix I-II-B-2. Host-Vector
2 Systems
Appendix I-III. Footnotes
and References of Appendix I
In consideration of biological
containment, the vector (plasmid, organelle, or virus) for the recombinant DNA
and the host (bacterial, plant, or animal cell) in which the vector is
propagated in the laboratory will be considered together. Any combination of vector and host which is
to provide biological containment shall be chosen or constructed so that the
following types of "escape" are minimized: (i) survival of the vector in its host outside the laboratory,
and (ii) transmission of the vector from the propagation host to other
non-laboratory hosts. The following
levels of biological containment (host-vector systems) for prokaryotes are
established. Appendices I-I-A through
I-II-B describe levels of biological containment (host-vector systems) for
prokaryotes. Specific criteria will
depend on the organisms to be used.
Host-Vector 1 systems
provide a moderate level of containment.
Specific Host-Vector 1 systems are:
The host is always Escherichia
coli K-12 or a derivative thereof, and the vectors include non-conjugative
plasmids (e.g., pSC101, ColE1, or derivatives thereof (see Appendices I-III-A through G, Footnotes and
References of Appendix I) and variants of bacteriophage, such as lambda
(see Appendices I-III-H through O, Footnotes
and References of Appendix I). The Escherichia
coli K-12 hosts shall not contain conjugation-proficient plasmids, whether
autonomous or integrated, or generalized transducing phages.
At a minimum, hosts
and vectors shall be comparable in containment to Escherichia coli K-12
with a non-conjugative plasmid or bacteriophage vector. Appendix
I-II, Certification of Host-Vector Systems, describes the data to be
considered and mechanism for approval of Host-Vector 1 systems.
Host-Vector 2 Systems
provide a high level of biological containment as demonstrated by data from
suitable tests performed in the laboratory.
Escape of the recombinant DNA either via survival of the organisms or
via transmission of recombinant DNA to other organisms should be < 1/108
under specified conditions. Specific
Host-Vector 2 systems are:
Appendix I-I-B-1. For Escherichia coli K-12 Host-Vector
2 systems (EK2) in which the vector is a plasmid, no more than 1/108
host cells shall perpetuate a cloned DNA fragment under the specified
non-permissive laboratory conditions designed to represent the natural
environment, either by survival of the original host or as a consequence of
transmission of the cloned DNA fragment.
Appendix I-I-B-2. For Escherichia coli K-12 Host-Vector
2 systems (EK2) in which the vector is a phage, no more than 1/108
phage particles shall perpetuate a cloned DNA fragment under the specified
non-permissive laboratory conditions designed to represent the natural
environment, either as a prophage (in the inserted or plasmid form) in the
laboratory host used for phage propagation, or survival in natural environments
and transferring a cloned DNA fragment to other hosts (or their resident
prophages).
Host-Vector 1 systems
(other than Escherichia coli K-12) and Host-Vector 2 systems may
not be designated as such until they have been certified by the NIH
Director. Requests for certification of
host-vector systems may be submitted to the Office of Biotechnology Activities,
National Institutes of Health, 6705 Rockledge Drive, Suite 750, MSC 7985,
Bethesda, MD 20892-7985 (20817 for
non-USPS mail), 301-496-9838, 301-496-9839 (fax). Proposed host-vector systems will be reviewed by the RAC (see Section
IV-C-1-b-(1)-(f), Major Actions).
Initial review will based on the construction, properties, and testing
of the proposed host-vector system by a subcommittee composed of one or more
RAC members and/or ad hoc experts.
The RAC will evaluate the subcommittee's report and any other available
information at the next scheduled RAC meeting.
The NIH Director is responsible for certification of host-vector
systems, following advice of the RAC.
Minor modifications to existing host-vector systems (i.e., those that
are of minimal or no consequence to the properties relevant to containment) may
be certified by the NIH Director without prior RAC review (see Section
IV-C-1-b-(2)-(f), Minor Actions).
Once a host-vector system has been certified by the NIH Director, a
notice of certification will be sent by NIH/OBA to the applicant and to the
Institutional Biosafety Committee Chairs.
A list of all currently certified host-vector systems is available from
the Office of Biotechnology Activities, National Institutes of Health, 6705
Rockledge Drive, Suite 750, MSC 7985, Bethesda, MD 20892-7985 (20817 for non-USPS mail), 301-496-9838, 301-496-9839
(fax). The NIH Director may rescind the
certification of a host-vector system (see Section
IV-C-1-b-(2)-(g), Minor Actions).
If certification is rescinded, NIH will instruct investigators to
transfer cloned DNA into a different system or use the clones at a higher level
of physical containment level, unless NIH determines that the already
constructed clones incorporate adequate biological containment. Certification of an host-vector system does
not extend to modifications of either the host or vector component of that
system. Such modified systems shall be
independently certified by the NIH Director.
If modifications are minor, it may only be necessary for the investigator
to submit data showing that the modifications have either improved or not
impaired the major phenotypic traits on which the containment of the system
depends. Substantial modifications to a
certified host-vector system requires submission of complete testing data.
The following types
of data shall be submitted, modified as appropriate for the particular system
under consideration: (i) a description of
the organism and vector; the strain's natural habitat and growth requirements;
its physiological properties, particularly those related to its reproduction,
survival, and the mechanisms by which it exchanges genetic information; the
range of organisms with which this organism normally exchanges genetic
information and the type of information is exchanged; and any relevant
information about its pathogenicity or toxicity; (ii) a description of the
history of the particular strains and vectors to be used, including data on any
mutations which render this organism less able to survive or transmit genetic
information; and (iii) a general description of the range of experiments
contemplated with emphasis on the need for developing such an Host-Vector 1
system.
Investigators
planning to request Host-Vector 2 systems certification may obtain instructions
from NIH/OBA concerning data to be submitted (see Appendices I-III-N and O, Footnotes
and References of Appendix I). In
general, the following types of data are required: (i) description of construction steps with indication of source,
properties, and manner of introduction of genetic traits; (ii) quantitative
data on the stability of genetic traits that contribute to the containment of
the system; (iii) data on the survival of the host-vector system under
non-permissive laboratory conditions designed to represent the relevant natural
environment; (iv) data on transmissibility of the vector and/or a cloned DNA
fragment under both permissive and non-permissive conditions; (v) data on all
other properties of the system which affect containment and utility, including
information on yields of phage or plasmid molecules, ease of DNA isolation, and
ease of transfection or transformation; and (vi) in some cases, the
investigator may be asked to submit data on survival and vector
transmissibility from experiments in which the host-vector is fed to laboratory
animals or one or more human subjects.
Such in vivo data may be required to confirm the validity of
predicting in vivo survival on the basis of in vitro
experiments. Data shall be submitted 12
weeks prior to the RAC meeting at which such data will be considered by the
Office of Biotechnology Activities, National Institutes of Health, 6705
Rockledge Drive, Suite 750, MSC 7985, Bethesda, MD 20892-7985 (20817 for non-USPS mail), 301-496-9838, 301-496-9839
(fax). Investigators are encouraged to publish their data on the construction,
properties, and testing of proposed Host Vector 2 systems prior to
consideration of the system by the RAC and its subcommittee. Specific instructions concerning the
submission of data for proposed Escherichia coli K-12 Host-Vector 2
system (EK2) involving either plasmids or bacteriophage in Escherichia coli
K-12, are available from the Office of Biotechnology Activities, National
Institutes of Health, 6705 Rockledge Drive, Suite 750, MSC 7985, Bethesda,
MD 20892-7985 (20817 for non-USPS
mail), 301-496-9838, 301-496-9839 (fax).
Appendix I-III-A. Hersfield, V., H. W. Boyer, C. Yanofsky, M.
A. Lovett, and D. R. Helinski, Plasmid Co1E1 as a Molecular Vehicle for
Cloning and Amplification of DNA.
Proc. Nat. Acad. Sci., 1974, 71, pp. 3455-3459.
Appendix I-III-B. Wensink, P. C., D. J. Finnegan, J. E.
Donelson, and D. S. Hogness, A System for Mapping DNA Sequences in the
Chromosomes of Drosophila Melanogaster.
Cell, 1974, 3, pp. 315-335.
Appendix I-III-C. Tanaka, T., and B. Weisblum, Construction
of a Colicin El-R Factor Composite Plasmid in Vitro: Means for Amplification of Deoxyribonucleic Acid. J. Bacteriol., 1975, 121, pp.
354-362.
Appendix I-III-D. Armstrong, K. A., V. Hershfield, and D. R. Helinski,
Gene Cloning and Containment Properties of Plasmid Col E1 and Its
Derivatives, Science, 1977, 196, pp. 172-174.
Appendix I-III-E. Bolivar, F., R. L. Rodriguez, M. C. Betlack,
and H. W. Boyer, Construction and Characterization of New Cloning Vehicles: I.
Ampicillin-Resistant Derivative of PMB9, Gene, 1977, 2, pp. 75-93.
Appendix I-III-F. Cohen, S. N., A. C. W. Chang, H. Boyer, and
R. Helling. Construction of Biologically Functional Bacterial Plasmids in
Vitro. Proc. Natl. Acad, Sci.,
1973, 70, pp. 3240-3244.
Appendix I-III-G. Bolivar, F., R. L. Rodriguez, R. J. Greene,
M. C.Batlack, H. L. Reyneker, H. W. Boyer, J. H. Cross, and S. Falkow, 1977, Construction
and Characterization of New Cloning Vehicles II. A Multi-Purpose Cloning System, Gene, 1977, 2, pp. 95-113.
Appendix I-III-H. Thomas, M., J. R. Cameron, and R. W. Davis
(1974). Viable Molecular Hybrids of
Bacteriophage Lambda and Eukaryotic DNA.
Proc. Nat. Acad. Sci., 1974, 71, pp. 4579-4583.
Appendix I-III-I. Murray, N. E., and K. Murray, Manipulation
of Restriction Targets in Phage Lambda to Form Receptor Chromosomes for DNA
Fragments. Nature, 1974, 51, pp. 476-481.
Appendix I-III-J. Ramback, A., and P. Tiollais (1974). Bacteriophage Having EcoRI Endonuclease
Sites Only in the Non-Essential Region of the Genome. Proc. Nat. Acad. Sci., 1974, 71, pp.
3927-3820.
Appendix I-III-K. Blattner, F. R., B. G. Williams, A. E.
Bleche, K. Denniston-Thompson, H. E. Faber, L. A. Furlong, D. J. Gunwald, D. O.
Kiefer, D. D. Moore, J. W. Shumm, E. L. Sheldon, and O. Smithies, Charon
Phages: Safer Derivatives of
Bacteriophage Lambda for DNA Cloning, Science 1977, 196, pp. 163-169.
Appendix I-III-L. Donoghue, D. J., and P. A. Sharp, An
Improved Lambda Vector: Construction of
Model Recombinants Coding for Kanamycin Resistance, Gene, 1977, 1, pp.
209-227.
Appendix I-III-M. Leder, P., D. Tiemeier and L. Enquist
(1977), EK2 Derivatives of Bacteriophage Lambda Useful in the Cloning of DNA
from Higher Organisms: The λgt WES System, Science,
1977, 196, pp. 175-177.
Appendix I-III-N. Skalka, A., Current Status of Coliphage
AEK2 Vectors, Gene, 1978, 3, pp. 29-35.
Appendix I-III-O. Szybalski, W., A. Skalka, S. Gottesman, A.
Campbell, and D. Botstein, Standardized Laboratory Tests for EK2
Certification, Gene, 1978, 3, pp. 36-38.